 that currently has no cure. It's only the second drug approved to treat Alzheimer's and has proven to only delay cognitive decline for a matter of months. The FDA approved Kisunla after an 18-month study showed patients taking the drug had a 22% slower decline than those who received a placebo. That is Fox's Tom Graham reporting. WHIO Newstime, 655.